Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Akari Therapeutics, Plc is a clinical-stage biotechnology firm dedicated to advancing novel treatments for autoimmune and inflammatory disorders. The company's primary investigational therapy is nomacopan, an advanced, second-generation complement inhibitor. This drug is engineered to counteract both inflammatory and prothrombotic processes. Nomacopan holds promise for a range of serious conditions, including paroxysmal nocturnal hemoglobinuria (PNH), Guillain-Barré syndrome (GBS), hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), and bullous pemphigoid (BP). Akari's operations are headquartered in London, United Kingdom.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers.
Target Price
The average target price of AKTX is 26.8 and suggests 87.6% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incr